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ABSTRACT
Objectives To approximate the rate of familial myasthenia
gravis and the coexistence of other autoimmune disorders
in the patients and their families.
Design Retrospective cohort study.
Setting Clinics across North America.
Participants The study included 1032 patients diagnosed
with acetylcholine receptor antibody (AChR)-positive
myasthenia gravis.
Methods Phenotype information of 1032 patients
diagnosed with AChR-positive myasthenia gravis was
obtained from clinics at 14 centres across North America
between January 2010 and January 2011. A critical review
of the epidemiological literature on the familial rate of
myasthenia gravis was also performed.
Results Among 1032 patients, 58 (5.6%) reported
a family history of myasthenia gravis. A history of
autoimmune diseases was present in 26.6% of patients
and in 28.4% of their family members.
Discussion The familial rate of myasthenia gravis was
higher than would be expected for a sporadic disease.
Furthermore, a high proportion of patients had a personal
or family history of autoimmune disease. Taken together,
these findings suggest a genetic contribution to the
pathogenesis of myasthenia gravis.

Strengths and limitations of this study
►► A strength of this study is that it analyses a large

cohort of patients with myasthenia gravis with complete data on each patient, allowing multiple clinical
correlations to be made.
►► A strength of this study is that standardised criteria were used to diagnose patients with myasthenia
gravis, including establishing the specific subtype of
the disease for each patient.
►► A strength of this study is that the cohort of patients
with myasthenia gravis was sufficiently large to allow the generation of evidence confirming a genetic
contribution to the disease.
►► A limitation of this study is the reliance on self-
reported family history status for both myasthenia gravis and other autoimmune diseases by the
patients.
►► A limitation of this study is its retrospective design,
which precludes ascertaining additional information
from individual patients.

junction was recognised.1 However, over the
past decade, additional autoimmune targets
have been identified: muscle-
specific tyroINTRODUCTION
sine kinase (MuSK), agrin and lipoprotein
Myasthenia gravis is a rare autoimmune receptor-related protein 4 (LRP4).2–4 All of
disease that is characterised by antibody- these proteins play essential roles in mainmediated interference with neuromuscular
taining the structure and function of the
transmission at the neuromuscular junction. neuromuscular junction.
Originally, the role for an autoimmune attack
Myasthenia gravis manifests clinically with
against the acetylcholine receptor (AChR) on muscle weakness and fatigability. Symptoms
the postsynaptic side of the neuromuscular of ocular muscle weakness are observed early
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in 85% of patients with myasthenia gravis.5 These symptoms include diplopia and/or ptosis. Weakness of the
bulbar musculature is observed in 60% of patients with
myasthenia gravis, with symptoms including dysarthria
and/or dysphagia.5
A recent literature review of 31 epidemiological studies
suggests that the annual incidence of myasthenia gravis
may range between 3 and 30 cases per million people.6
A common theme among myasthenia gravis epidemiological studies is that there is a significant degree of variability between cohorts. For example, a study of a Hong
Kong Chinese cohort reported an incidence of 4 per
million people per year, whereas a study of an English
cohort reported an incidence of 30 per million people
per year.7 8 This substantial degree of variability may be
the result of inconsistent diagnostic criteria, varying case
ascertainment, lack of physician awareness concerning
myasthenia gravis or it may reflect different occurrence
across populations.
Historically, adult-
onset myasthenia gravis has been
regarded as a sporadic disease with only a minimal
genetic component.9 However, genome-
wide association studies, fine-mapping studies and epidemiological
studies of myasthenia gravis suggest a genetic contribution to the disease.10 11 In fact, studies have described
patients with myasthenia gravis that have a family history
of myasthenia gravis and/or a family history of autoimmune diseases.12–16 In this study, we performed a literature search of the familial rate reported by myasthenia
gravis epidemiological studies and, using our cohort of
1032 North American patients with myasthenia gravis,
approximated the prevalence of familial myasthenia
gravis, compared the characteristics of familial disease
with sporadic disease and assessed the comorbidity of
other autoimmune diseases among patients and among
their families.
METHODS
Patient ascertainment
Phenotype information of 1032 patients diagnosed with
myasthenia gravis was obtained from myasthenia gravis
clinics at 14 centres across North America between January
2010 and January 2011.10 The numbers of patients with
myasthenia gravis attending each of these clinics were not
available for this study. Patients were diagnosed by neurologists specialising in myasthenia gravis. Each myasthenia
gravis diagnosis was based on standard clinical criteria
that included, but was not limited to, weakness, fatigability
and electrophysiological, pharmacological (edrophonium test) and/or serological abnormalities. Inclusion
criteria for this study were as follows: confirmed diagnosis of myasthenia gravis, non-Hispanic white ethnicity
and the presence of anti-AChR antibodies. Patients with
anti-MuSK antibodies were excluded from the study. The
LRP4 antibody was discovered after the collection of the
cohort was complete. Thus, the LRP4 antibody status of
the patients was not known. Family histories of myasthenia
2

gravis and other autoimmune diseases were systematically
obtained for each subject using a simple structured questionnaire (see online supplementary table S1). A positive
family history was defined as having a first-degree (~50%
of DNA in common), second-degree (~25% of DNA in
common) or third-degree (~12.5% of DNA in common)
relative with the disease. DNA samples were collected
from each subject and used for genetic analyses as previously reported.10 Patients with genetic forms of myasthenia gravis were not explicitly excluded, though none
in the cohort was known to have such a mutation.
Literature review methodology
To find studies about the epidemiology of familial myasthenia gravis, the PubMed and Medline databases were
searched using permutations of search terms: ‘epidemiology of familial myasthenia gravis’, ‘epidemiology of
myasthenia gravis’ and ‘heritability of myasthenia gravis’.
After reviewing 31 epidemiological studies between the
years of 1950 through 2018, only 10 studies explicitly
referenced a family history of myasthenia gravis. Five of
those papers provided metrics about family members
with myasthenia gravis.12–16
Patient and public involvement statement
No patients or members of the public were actively
involved with co-producing the research presented in this
article.

RESULTS
North American cohort of patients with myasthenia gravis
Clinical data were collected from a total of 1032 patients
across 14 centres in North America and were analysed
in this study. All of the patients had positive anti-AChR
antibodies. The median age of symptom onset in this
clinic-
based cohort was 58 years of age (range=4–91;
median onset age for females=46; median onset age for
males=62). The female-
to-
male ratio was 1:1.27. Early-
onset disease (<40 years of age) was observed among 248
(24.0%) of the cohort. Consistent with other reports,
nearly one-third of the patients in our North American
study cohort (305, 29.6%) had undergone thymectomy.
Fifty-eight (5.6%) patients had a family history of myasthenia gravis. Sibling–sibling (31.0%) and parent–child
(32.8%) were the most common types of familial relationship, followed by uncle/aunt–nephew/niece (13.8%),
cousin–cousin (12.1%) and grandparent–grandchild
(5.2%) relationships. Of note, the indicated percentage
of parent–child cases might be inflated because neonatal
myasthenia gravis cases (which are not believed to be
genetic) could not be discerned from non-neonatal cases.
Age at symptom onset was similar among patients with
a family history compared with patients without a family
history (57.5 years of age, range=8–80 years vs 58.5 years,
range=4–91 years, p value=0.183, Wilcoxon rank-sum test,
figure 1, table 1).
Green JD, et al. BMJ Open 2020;10:e037909. doi:10.1136/bmjopen-2020-037909
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and rheumatoid arthritis (n=28, 2.7%). This was similar
to the rates previously reported by Mao et al (figure 2C).18
The three most common autoimmune diseases present
in the families of patients with myasthenia gravis were
thyroid disease (n=98, 9.5%), rheumatoid arthritis (n=68,
6.6%) and type 1 diabetes (n=36, 3.5%).

Figure 1 Symptom-onset age distribution of sporadic and
familial cases. The density represents the relative probability
of myasthenia gravis at each age point.

A personal history of an autoimmune disease other
than myasthenia gravis was reported in 275 (26.6%) of
study participants. A total of 293 (28.4%) subjects had
a family history of an autoimmune disease. The prevalence of autoimmune disease in the general population
is ~3%–9%, indicating that the rates observed among our
myasthenia gravis subjects are significantly increased.17 A
breakdown of the specific autoimmune diseases for both
personal history and family history of disease is shown in
figure 2A,B.
The most common autoimmune diseases present
concomitantly in patients with myasthenia gravis were
thyroid disease (n=118, 11.4%), haematological disease
(n=33, 3.2% consisting of autoimmune haemolytic
anaemia and autoimmune thrombocytopenic purpura)

Table 1 Comparison of familial and sporadic cases among
a cohort of patients diagnosed with myasthenia gravis
(n=1032)
Familial

Sporadic

P value

Number of
myasthenia
gravis cases (%)

58 (5.6)

974 (94.4)

–

Median age of
disease onset
(years) (range)

57.5 (8–80)

Number of
patients with
early-onset
disease (<40
years) (%)

15 (25.9)

233 (23.9)

0.86

Number of
females (%)

25 (43.1)

429 (44.0)

0.997

58.5 (4–91)

0.183

Green JD, et al. BMJ Open 2020;10:e037909. doi:10.1136/bmjopen-2020-037909

Literature review
Literature review concerning the epidemiology of familial
myasthenia gravis identified five studies that discussed
the patient’s family history of myasthenia gravis with
sample sizes that ranged from 264 to 6638 (table 2).12–16
The frequency of familial myasthenia gravis ranged from
0.2% to 7.2% across studies, the upper limit having been
reported for a Finnish cohort.15 Among these, three
studies reported that familial myasthenia gravis cases
had an earlier symptom onset age than the sporadic
cases.12 14 15 Only three studies reported on the patient
history of other autoimmune diseases and/or on the
family history of other autoimmune diseases.12 14 15 Among
these, thyroid disease, rheumatoid arthritis, systemic
lupus erythematosus and Sjogren’s syndrome were the
most common other autoimmune diseases reported in
patients’ personal and/or family histories.12 14 15

DISCUSSION
We found the prevalence of familial myasthenia gravis
in our North American cohort to be 5.6%. Our previous
genetic analysis of this cohort showed the heritability
of myasthenia gravis to be 25.5%.10 This is comparable
to the prevalence reported in other studies, where the
frequency ranged from 0.2% to 7.2% of patients with
myasthenia gravis having a family history of myasthenia
gravis depending on the cohort studied.12–16 Although
the vast majority of myasthenia gravis cases are still
non-familial, a prevalence of 5.6% represents a several
hundred-fold increase for a disease with an overall prevalence of 1 in 5–10 000.5 The two studies of myasthenia
gravis based on Asian cohorts reported substantially lower
rates of familial disease compared with our North American cohort and other European cohorts. For example,
two studies of Taiwanese (n=6638) and Japanese (n=3141)
cohorts reported rates of familial myasthenia gravis at
0.2% and 0.7%, respectively.12 13 Three studies of Spanish,
American, and Finnish cohorts reported rates of 3.5%,
3.8% and 7.2% (table 2).14–16 The familial rate reported
in our cohort of over 1000 patients were, as expected,
closer in value to the rates reported among European and
American cohorts. Overall, these data suggest that there
is population variation in the inheritance of myasthenia
gravis that warrants further study to identify the genetic
contribution to disease risk.
A notable feature of our cohort is that males had a
slightly higher prevalence of familial myasthenia gravis
compared with females (1:1.32), suggesting that there
might be sex-specific differences in the occurrence of
familial versus sporadic disease. This observation may
3
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Figure 2 Autoimmune diseases in a cohort of 1032 patients with myasthenia gravis. (A) Occurrence of autoimmune diseases
among patients with myasthenia gravis (n=275). (B) Occurrence of autoimmune diseases among familial relatives of patients
with myasthenia gravis (n=293). (C) Comparisons of autoimmune diseases among patients with myasthenia gravis and among
relatives. Size of each circle represents the percentage previously reported by Mao et al.18

reflect the different age distribution of myasthenia gravis
cases in males versus females observed across all myasthenia gravis cases. The reason for this is unclear, though
we note that our previous genome-wide association study
of myasthenia gravis indicated that the genetic architecture was different among younger and older age groups.10
Myasthenia gravis is an immunological disorder and,
generally speaking, autoimmune diseases are known to
have heritable components.19 Likewise, approximately
one-third of our cohort had a personal history and/or a
Table 2 Studies reporting the rate of familial disease in
myasthenia gravis
Source

Origin

Sample
size

Familial
rate (%)

Study type

12
13

Taiwan
Japan

6638
3141

0.2
0.7

Population
Population

14

Spain

462

3.5

Clinic

15
16

Finland
United
States

264
702

7.2
3.8

Population
Clinic

4

family history of another autoimmune disease, which is
much higher than the prevalence of 3%–9%, which has
been historically reported in the general population.17
We found that 19% (11/58) of the familial myasthenia
gravis cases also had a personal history of autoimmune
diseases; this was more than the sporadic myasthenia
gravis cases in which only 10% (98/974) had a personal
history of autoimmune diseases. Similar to previous
reports, we found thyroid disease, rheumatoid arthritis,
systemic lupus erythematosus and type 1 diabetes
to be the most commonly identified comorbidities
(figure 2C).18 19 Interestingly, the frequency of thyroid
disease in this cohort (11.4%) is similar to the frequency
range of thyroid disease reported in a study by Kiessling
et al.20 The increased prevalence of familial myasthenia
gravis and increased prevalence of other autoimmune
disorders both suggest that these autoimmune diseases
may share a common predisposition that may be genetic
in origin. We speculate that the link between thyroid
disease and myasthenia gravis may be due to a common
genetic background or an immunological cross-reactivity
against epitopes or auto-antigens shared by the thyroid
and other tissues relevant to myasthenia gravis.21 22 Future
Green JD, et al. BMJ Open 2020;10:e037909. doi:10.1136/bmjopen-2020-037909
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studies focusing on specific genes and genomic variants
encountered in patients with familial myasthenia gravis
offer the promise to more precisely identify any genetic
contributions to the disease.
While our study has some notable strengths, it also
has an inherent limitation related to its reliance on self-
reported family histories, which could have overestimated or underestimated the prevalence of the diseases
studied. For example, it is plausible that a patient could
self-report as not having a family history of myasthenia
gravis because a family member was never clinically diagnosed with the disease or did not live long enough for the
disease to manifest. Similarly, other studies have found
an overestimation of some autoimmune diseases, especially thyroid disease and rheumatoid arthritis, related to
self-reporting.23
Our analyses provide evidence of a genetic contribution
to myasthenia gravis based on the higher than expected
rate of familial disease observed among our North American patient cohort as well as the co-occurrence of autoimmune diseases known to have a genetic basis among
this population. More work needs to be done to further
elucidate the genetic aetiology of this archetypal autoimmune disease.
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